Clinical Scorecard: ATSN-201 Gene Therapy Shows Improvement in XLRS at 18 Months
At a Glance
| Category | Detail |
|---|---|
| Condition | X-linked retinoschisis (XLRS) |
| Key Mechanisms | Gene therapy using ATSN-201 with AAV.SPR capsid targeting central photoreceptors. |
| Target Population | Adults with X-linked retinoschisis |
| Care Setting | Clinical trial setting |
Key Highlights
- Sustained structural and functional changes observed at 18 months post-treatment.
- Foveal schisis closure maintained in 7 of 9 treated eyes.
- Six treated eyes showed improvement of at least 7 dB on microperimetry.
- Seven treated eyes had gains of at least 10 letters in visual acuity.
- No serious adverse events or treatment discontinuations reported.
Guideline-Based Recommendations
Diagnosis
- Clinical evaluation of visual acuity and microperimetry for XLRS.
Management
- Consider ATSN-201 gene therapy for eligible adults with XLRS.
Monitoring & Follow-up
- Regular follow-up on visual acuity and structural changes post-treatment.
Risks
- Monitor for potential adverse events, although none reported in the study.
Patient & Prescribing Data
Adults with X-linked retinoschisis participating in the LIGHTHOUSE trial.
ATSN-201 administered via subretinal injection showed promising results in structural and functional improvements.
Clinical Best Practices
- Evaluate patients for eligibility in gene therapy trials.
- Utilize microperimetry for assessing functional changes in vision.
- Monitor patients closely for any adverse effects post-injection.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.